Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.

doi:10.1093/jnci/djs458

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.

Journal of the National Cancer Institute - 2 Jan 2013

Kohaar Indu, Porter-Gill Patricia, Lenz Petra, Fu Yi-Ping, Mumy Adam, Tang Wei, Apolo Andrea B, Rothman Nathaniel, Baris Dalsu, Schned Alan R, Ylaya Kris, Schwenn Molly, Johnson Alison, Jones Michael, Kida Masatoshi, Silverman Debra T, Hewitt Stephen M, Moore Lee E, Prokunina-Olsson Ludmila

Abstract excerpt

A monoclonal antibody against prostate stem cell antigen (PSCA) has emerged as a novel cancer therapy currently being tested in clinical trials for prostate and pancreatic cancers, but this treatment is likely to be efficient only in patients with PSCA-expressing tumors. The present study demonstrates that a genetic variant (rs2294008) discovered by bladder cancer genome-wide association studies is a strong...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GPI-Linked Proteins

Share to Immunotherapy

Share to Linear Models

Share to Multivariate Analysis

Share to Neoplasm Proteins

Share to Predictive Value of Tests

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 23266392
DOI: 10.1093/jnci/djs458
PMCID: PMC3536639

Genes

PSCA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.PMID 23266392Read ↗

Prostate stem cell antigen rs2294008 (C>T) polymorphism and bladder cancer risk: a meta-analysis based on cases and controls.Semantic proximity Read ↗

Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk.Semantic proximity Read ↗

Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population.Semantic proximity Read ↗

Genetic variation in PSCA is associated with bladder cancer susceptibility in a Korean population.Semantic proximity Read ↗

Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer.Semantic proximity Read ↗

PSCA rs2294008 Polymorphism with Increased Risk of Cancer.Semantic proximity Read ↗

Single Nucleotide Polymorphism in PSCA Associated with Bladder Cancer Susceptibility in an Indian SubpopulationSemantic proximity Read ↗

Evolution of the concept of androgen-sensitive bladder cancer.Semantic proximity Read ↗

Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?Semantic proximity Read ↗

PSCArs2294008 T polymorphism increases the risk of bladder cancer in Bai, Dai, and Han ethnicity in China and a potential mechanism.Semantic proximity Read ↗

Genetic score of multiple risk-associated single nucleotide polymorphisms is a marker for genetic susceptibility to bladder cancer.Semantic proximity Read ↗

Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.